Overcoming the Global Biomaterial Supply Chain Challenge for the Development of CAR-T Therapies
By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest share of oncology drug sales for pediatric and young adult patients1. This is […]